Frontiers in Psychiatry
February 6, 2023
Candace R. Lewis, Joseph Tafur, Sophie Spencer et al.
29 citations
BackgroundPrevious research has demonstrated that epigenetic changes in specific hypothalamic-pituitary-adrenal (HPA) genes may predict successful psychotherapy in post-traumatic stress disorder (PTSD). A recent Phase 3 clinical trial reported high efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for treating patients with severe PTSD compared to a therapy with placebo...
Trends in Cognitive Sciences
February 3, 2023
Manesh Girn, Fernando E. Rosas, Richard E. Daws et al.
76 citations
Recent findings suggesting the potential transdiagnostic efficacy of psychedelic-assisted therapy have fostered the need to deepen our understanding of psychedelic brain action. Functional neuroimaging investigations have found that psychedelics reduce the functional segregation of large-scale brain networks. However, beyond this general trend, findings have been largely inconsistent. We argue...
Comprehensive Psychoneuroendocrinology
February 1, 2023
Daniel Rødbro Burmester, Martin Korsbak Madsen, Attila Szabo et al.
24 citations
Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonergic psychedelics, have anti-inflammatory effects. This may contribute to its therapeutic effects as previous...
JMIR Research Protocols
January 27, 2023
Yuliya Knyahnytska, Reza Zomorrodi, Tyler S Kaster et al.
Suicide is among the top 10 leading causes of death worldwide. Of people who died by suicide, the majority are diagnosed with depression. It is estimated that 25%-60% of people with bipolar depression (BD) will attempt suicide at least once, and 10%-15% will die by suicide. Several treatments, such as lithium, clozapine, electroconvulsive therapy, and cognitive behavioral therapy, have been...
ACS Medicinal Chemistry Letters
January 18, 2023
Robert B. Kargbo
2 citations
The renaissance of research into psychedelics class of drugs has renewed interest for a possible psychedelic clinical therapy for treating psychiatric conditions such as treatment-resistant depression, major depressive-disorder, post-traumatic stress disorder, and other neuropsychiatric diseases. Psychedelics are known to stimulate neurogenesis and gliogenesis, reduce inflammation, and...
International Journal of Molecular Sciences
January 10, 2023
Andrea Mastinu, Margrate Anyanwu, Marinella Carone et al.
45 citations
The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics. For several years there has been growing interest among psychotherapists in psilocybin or lysergic acid...
Open Access Government
January 6, 2023
Tadeusz Hawrot, David R. Badcock
Brain health conditions: Excellence in psychedelic treatments Psychedelic treatments open up an unparalleled window of opportunity, but we need to get ready for their roll-out. Mental healthcare is in crisis, and we don't have the tools to truly help millions of Europeans in need. In the EU, a shocking number of over 100 million people are affected by mental health conditions and alcohol use...
International Journal of Whole Person Care
January 6, 2023
Houman Farzin
1 citation
eath is of the most certain and undeniable truths in an existence shrouded by mysteries and unknowns, yet many don't have the opportunity for a meaningful reflection on this matter until the very end of their life.Existential suffering often awaits at death's door while effective solutions remain limited.The reality is that saving lives has been a key pillar of our medical ethos and so the...
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
January 5, 2023
Kaden Venugopal, Nefissa Bedri
5 citations
Introduction: Psilocybin (the active compound found in “magic mushrooms”) has been an area of recent focus in the academic and psychiatric community on account of its potential in treating a spectrum of substance use and concurrent disorders (SUCDs). This paper posits a literature review of the current research pertaining to psilocybin in treating alcohol use disorder (AUD) through a form of...
January 4, 2023
Sidsel Dahl Andersen
preprint
Self or ego dissolution (SED) is a recurring, yet vaguely defined phenomenon often associated with positive therapeutic outcomes within clinical research on classic psychedelic substances. The aim of this thesis is to achieve a deeper understanding and improve terminological clarity of SED in a psychedelic context, here defined as research settings in which moderate to high doses of psilocybin...